LIMP2 Antibody
| Code | Size | Price |
|---|
| PSI-4655-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-4655-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
LIMP2 Antibody: AMRF, EPM4, LGP85, CD36L2, HLGP85, LIMP-2, LIMPII, SR-BII, LIMP2, Lysosome membrane protein 2, 85 kDa lysosomal membrane sialoglycoprotein
Application Note:
LIMP2 antibody can be used for detection of LIMP2 by Western blot at 1 and 2 μg/mL. Despite its predicted molecular weight, LIMP2 runs at approximately 80 - 85 kDa in SDS-PAGE. Antibody can also be used for immunohistochemistry starting at 10 μg/mL.
Antibody validated: Western Blot in human samples and Immunohistochemistry in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples and Immunohistochemistry in human samples. All other applications and species not yet tested.
Background:
LIMP2 Antibody: The lysosomal integral membrane protein 2 (LIMP2) is a heavily glycosylated type III transmembrane protein, the majority of which exists in the lumen of the lysosome and a cytoplasmic domain of approximately 20 amino acids. A deficiency of LIMP2 in mice causes uretic pelvic junction obstruction, deafness, and peripheral neuropathy associated with impaired vesicular trafficking and distribution of apically expressed proteins. More recently, LIMP2 was shown to act as a receptor to bind beta-glucocerebrosidase, the enzyme defective in Gaucher disease, a lysosomal storage disorder. LIMP2-deficient mice showed missorted as well as secreted beta-glucocerebrosidase, suggesting that LIMP2 also functions as the mannose-6-phosphate-independent trafficking receptor.
Background References:
- Fujita H, Saeki M, Yasunaga K, et al. Isolation and sequencing of a cDNA clone encoding 85kDa sialoglycoprotein in rat liver lysosomal membranes. Biochem. Biophys. Res. Commun.1991; 178:444-52.
- Gamp A, Tanaka Y, Lullmann-Rauch R, et al. LIMP-2/LGP85 deficiency causes uretic pelvic junction obstruction, deafness and peripheral neuropathy in mice. Hum. Mol. Genet.2003; 12:631-46.
- Knipper M, Claussen C, Ruttiger L, et al. Deafness in LIMP2-deficient mice due to early loss of the potassium channel KCNQ1/KCNE1 in marginal cells of the stria vascularis. J. Physiol.2006; 576:73-86.
- Reczek D, Schwake M, Schroder J, et al. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of b-glucocerebrosidase. Cell2007; 131:770-83.
Buffer:
LIMP2 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Rat: (89%)
Immunogen:
LIMP2 antibody was raised against a 18 amino acid synthetic peptide from near the carboxy terminus of human LIMP2.
The immunogen is located within the last 50 amino acids of LIMP2.
The immunogen is located within the last 50 amino acids of LIMP2.
NCBI Gene ID #:
950
NCBI Official Name:
scavenger receptor class B, member 2
NCBI Official Symbol:
SCARB2
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
AAH21892
Protein GI Number:
18257312
Purification:
LIMP2 Antibody is affinity chromatography purified via peptide column.
Research Area:
Homeostasis
Swissprot #:
Q14108
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | LIMP2 Peptide | PSI-4655P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|